Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Adrian Mander"'
Autor:
Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial repor
Externí odkaz:
https://doaj.org/article/81ef4cb13be84637b253963b7331df99
Autor:
Tomi Suomi, Inna Starskaia, Ubaid Ullah Kalim, Omid Rasool, Maria K. Jaakkola, Toni Grönroos, Tommi Välikangas, Caroline Brorsson, Gianluca Mazzoni, Sylvaine Bruggraber, Lut Overbergh, David Dunger, Mark Peakman, Piotr Chmura, Søren Brunak, Anke M. Schulte, Chantal Mathieu, Mikael Knip, Riitta Lahesmaa, Laura L. Elo, Pieter Gillard, Kristina Casteels, Lutgart Overbergh, Chris Wallace, Mark Evans, Ajay Thankamony, Emile Hendriks, Loredana Marcoveccchio, Timothy Tree, Noel G. Morgan, Sarah Richardson, John A. Todd, Linda Wicker, Adrian Mander, Colin Dayan, Mohammad Alhadj Ali, Thomas Pieber, Decio L. Eizirik, Myriam Cnop, Flemming Pociot, Jesper Johannesen, Peter Rossing, Cristina Legido Quigley, Roberto Mallone, Raphael Scharfmann, Christian Boitard, Timo Otonkoski, Riitta Veijola, Matej Oresic, Jorma Toppari, Thomas Danne, Anette G. Ziegler, Peter Achenbach, Teresa Rodriguez-Calvo, Michele Solimena, Ezio E. Bonifacio, Stephan Speier, Reinhard Holl, Francesco Dotta, Francesco Chiarelli, Piero Marchetti, Emanuele Bosi, Stefano Cianfarani, Paolo Ciampalini, Carine De Beaufort, Knut Dahl-Jørgensen, Torild Skrivarhaug, Geir Joner, Lars Krogvold, Przemka Jarosz-Chobot, Tadej Battelino, Bernard Thorens, Martin Gotthardt, Bart O. Roep, Tanja Nikolic, Arnaud Zaldumbide, Ake Lernmark, Marcus Lundgren, Guillaume Costacalde, Thorsten Strube, Almut Nitsche, Jose Vela, Matthias Von Herrath, Johnna Wesley, Antonella Napolitano-Rosen, Melissa Thomas, Nanette Schloot, Allison Goldfine, Frank Waldron-Lynch, Jill Kompa, Aruna Vedala, Nicole Hartmann, Gwenaelle Nicolas, Jean van Rampelbergh, Nicolas Bovy, Sanjoy Dutta, Jeannette Soderberg, Simi Ahmed, Frank Martin, Esther Latres, Gina Agiostratidou, Anne Koralova, Ruben Willemsen, Anne Smith, Binu Anand, Vipan Datta, Vijith Puthi, Sagen Zac-Varghese, Renuka Dias, Premkumar Sundaram, Bijay Vaidya, Catherine Patterson, Katharine Owen, Barbara Piel, Simon Heller, Tabitha Randell, Tasso Gazis, Elise Bismuth Reismen, Jean-Claude Carel, Jean-Pierre Riveline, Jean-Francoise Gautier, Fabrizion Andreelli, Florence Travert, Emmanuel Cosson, Alfred Penfornis, Catherine Petit, Bruno Feve, Nadine Lucidarme, Jean-Paul Beressi, Catherina Ajzenman, Alina Radu, Stephanie Greteau-Hamoumou, Cecile Bibal, Thomas Meissner, Bettina Heidtmann, Sonia Toni, Birgit Rami-Merhar, Bart Eeckhout, Bernard Peene, N. Vantongerloo, Toon Maes, Leen Gommers
Publikováno v:
EBioMedicine, Vol 92, Iss , Pp 104625- (2023)
Summary: Background: Type 1 diabetes is a complex heterogenous autoimmune disease without therapeutic interventions available to prevent or reverse the disease. This study aimed to identify transcriptional changes associated with the disease progress
Externí odkaz:
https://doaj.org/article/2c41bdea112542e1901b5cf0742fc2e4
Autor:
Sally Hopewell, An-Wen Chan, Christopher Weir, Adrian Mander, Rong Liu, Christina Yap, Johann De Bono, Khadija Rantell, Munyaradzi Dimairo, Thomas Jaki, Alun Bedding, Aude Espinasse, Olga Solovyeva, Andrew Kightley, Jeffry Evans, Shing Lee
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Introduction Early phase dose-finding (EPDF) studies are critical for the development of new treatments, directly influencing whether compounds or interventions can be investigated in further trials to confirm their safety and efficacy. There exists
Externí odkaz:
https://doaj.org/article/34d40429be3b495887a92c6a928261b1
Autor:
Howard Ring, James Howlett, Mark Pennington, Christopher Smith, Marcus Redley, Caroline Murphy, Roxanne Hook, Adam Platt, Nakita Gilbert, Elizabeth Jones, Joanna Kelly, Angela Pullen, Adrian Mander, Cam Donaldson, Simon Rowe, James Wason, Fiona Irvine
Publikováno v:
Health Technology Assessment, Vol 22, Iss 10 (2018)
Background: People with an intellectual (learning) disability (ID) and epilepsy have an increased seizure frequency, higher frequencies of multiple antiepileptic drug (AED) use and side effects, higher treatment costs, higher mortality rates and more
Externí odkaz:
https://doaj.org/article/36123d071c1b4fce85fdd8e27c3a7c04
Publikováno v:
Journal of Statistical Software, Vol 54, Iss 1, Pp 1-26 (2013)
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment method (CRM) designs in Phase I dose-escalation trials. CRM designsare a class of adaptive design that select the dose to be given to the next recruit
Externí odkaz:
https://doaj.org/article/88744fe01ce94de5b70835aea019e3c5
Autor:
Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander, Andrew Kightley, Jeffry Evans, Shing Lee, Alun Bedding, Sally Hopewell, Khadija Rantell, Rong Liu, An-Wen Chan, Johann De Bono, Christina Yap
Publikováno v:
Espinasse, A, Solovyeva, O, Dimairo, M, Weir, C J, Jaki, T, Mander, A, Kightley, A, Evans, J, Lee, S M, Bedding, A, Hopewell, S, Rantell, K, Liu, R, Chan, A-W, de Bono, J & Yap, C 2023, ' SPIRIT and CONSORT extensions for early phase dose-finding clinical trials : the DEFINE (DosE FIndiNg Extensions) study protocol ', BMJ Open, vol. 13, no. 3, e068173, pp. e068173 . https://doi.org/10.1136/bmjopen-2022-068173
IntroductionEarly phase dose-finding (EPDF) studies are critical for the development of new treatments, directly influencing whether compounds or interventions can be investigated in further trials to confirm their safety and efficacy. There exists g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4dc3e3f6961e75dbfa3d23e2bdf0b2
https://www.pure.ed.ac.uk/ws/files/334543633/BMJ_Open_DEFINE_Protocol_Paper_v3.5_revised_final.pdf
https://www.pure.ed.ac.uk/ws/files/334543633/BMJ_Open_DEFINE_Protocol_Paper_v3.5_revised_final.pdf
Publikováno v:
Pharmaceutical statistics
Summary Randomised controlled trials are considered the gold standard in trial design. However, phase II oncology trials with a binary outcome are often single-arm. Although a number of reasons exist for choosing a single-arm trial, the primary reaso
Autor:
Christina Yap, Alun Bedding, Johann de Bono, Munyaradzi Dimairo, Aude Espinasse, Jeffry Evans, Sally Hopewell, Thomas Jaki, Andrew Kightley, Shing Lee, Rong Liu, Adrian Mander, Olga Solovyeva, Christopher J. Weir
Publikováno v:
Yap, C, Bedding, A W, de Bono, J, Dimairo, M, Espinasse, A, Evans, T R J, Hopewell, S, Jaki, T, Kightley, A, Lee, S, Liu, R, Mander, A P, Solovyeva, O & Weir, C J 2022, ' The need for reporting guidelines for early phase dose-finding trials : Dose-Finding CONSORT Extension ', Nature Medicine, vol. 28, pp. 6-7 . https://doi.org/10.1038/s41591-021-01594-1
Autor:
S. Faye Williamson, Michael Grayling, Adrian Mander, Nurulamin Noor, Joshua Savage, Christina Yap, James Wason
Publikováno v:
SSRN Electronic Journal.
Autor:
Charlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Mark Wilson, Katrina Gatley, Anita Chhabra, M Loredana Marcovecchio, A Emile J Hendriks, Hilde Morobé, Piotr Jaroslaw Chmura, Simon Bond, Bärbel Aschemeier-Fuchs, Mikael Knip, Timothy Tree, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Michael J Haller, Almut Nitsche, Anke M Schulte, Chantal Mathieu, Adrian Mander, David Dunger
Publikováno v:
BMJ Open
Wilhelm-Benartzi, C S, Miller, S E, Bruggraber, S, Picton, D, Wilson, M, Gatley, K, Chhabra, A, Marcovecchio, M L, Hendriks, A E J, Morobé, H, Chmura, P J, Bond, S, Aschemeier-Fuchs, B, Knip, M, Tree, T, Overbergh, L, Pall, J, Arnaud, O, Haller, M J, Nitsche, A, Schulte, A M, Mathieu, C, Mander, A & Dunger, D 2021, ' Study protocol Minimum effective low dose: Anti-human thymocyte globulin (MELD-ATG) : Phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes ', BMJ Open, vol. 11, no. 12, e053669 . https://doi.org/10.1136/bmjopen-2021-053669
BMJ OPen
Wilhelm-Benartzi, C S, Miller, S E, Bruggraber, S, Picton, D, Wilson, M, Gatley, K, Chhabra, A, Marcovecchio, M L, Hendriks, A E J, Morobé, H, Chmura, P J, Bond, S, Aschemeier-Fuchs, B, Knip, M, Tree, T, Overbergh, L, Pall, J, Arnaud, O, Haller, M J, Nitsche, A, Schulte, A M, Mathieu, C, Mander, A & Dunger, D 2021, ' Study protocol Minimum effective low dose: Anti-human thymocyte globulin (MELD-ATG) : Phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes ', BMJ Open, vol. 11, no. 12, e053669 . https://doi.org/10.1136/bmjopen-2021-053669
BMJ OPen
• Introduction: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc0f7f45d778801769d91a723bd536ad